Eton Pharmaceuticals (NASDAQ:ETON) Upgraded at Zacks Research

Zacks Research upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) from a hold rating to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Several other research firms have also recently weighed in on ETON. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. HC Wainwright boosted their target price on Eton Pharmaceuticals from $37.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Finally, B. Riley Financial increased their price target on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Eton Pharmaceuticals Trading Up 7.5%

NASDAQ ETON opened at $22.32 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The company has a market cap of $598.62 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. The business’s fifty day moving average is $16.72 and its 200 day moving average is $17.38. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). The firm had revenue of $21.28 million during the quarter, compared to the consensus estimate of $20.58 million. Eton Pharmaceuticals had a negative return on equity of 2.66% and a negative net margin of 5.75%. As a group, sell-side analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. Opaleye Management Inc. raised its holdings in shares of Eton Pharmaceuticals by 0.3% in the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares during the period. EcoR1 Capital LLC grew its holdings in Eton Pharmaceuticals by 2.0% during the second quarter. EcoR1 Capital LLC now owns 2,030,544 shares of the company’s stock valued at $28,935,000 after purchasing an additional 40,756 shares during the period. Vanguard Group Inc. increased its position in Eton Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after buying an additional 31,942 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Eton Pharmaceuticals by 98.8% in the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after buying an additional 294,617 shares during the period. Finally, State Street Corp lifted its position in shares of Eton Pharmaceuticals by 14.5% during the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after buying an additional 63,480 shares during the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.